Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
French biotech company Ipsen is acquiring Kartos Therapeutics for up to $1.75 billion to expand its blood cancer pipeline.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront, with a total deal value of up to $1.75 billion. The acquisition was intended to expand Ipsen's hemato-oncology late-stage pipeline and strengthen its hematology franchise.
The deal included a blood cancer asset for a potential Jakafi add-on therapy for myelofibrosis.
Epilogue added 14d ago, after coverage quieted.
The brief
Ipsen has entered an agreement to acquire Kartos Therapeutics. The deal includes an upfront payment of $450 million, with the total value potentially reaching $1.75 billion.
Coverage from Reuters, the Wall Street Journal, and Fierce Biotech emphasizes that the acquisition is aimed at expanding Ipsen's late-stage hemato-oncology pipeline. Specifically, Fierce Biotech notes the deal involves a potential Jakafi add-on therapy for myelofibrosis.
Future developments center on the integration of Kartos' blood cancer research into Ipsen's existing portfolio and the progression of the late-stage pipeline.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 21d ago.
Quick answers
What is the total potential value of the acquisition?
The deal is valued for up to $1.75 billion according to the Wall Street Journal.
How much is being paid upfront?
According to Reuters and Endpoints News, Ipsen will pay $450 million upfront.
What specific therapy is associated with this deal?
Fierce Biotech reports the acquisition targets a potential Jakafi add-on therapy for myelofibrosis.
Coverage (7)
- Ipsen strengthens its hematology franchise with the acquisition of Kartos Therapeutics marketscreener.com · 22d ago
- Ipsen to pay $1.75B for Kartos and its blood cancer asset FirstWord Pharma · 22d ago
- Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline GlobeNewswire · 22d ago
- French biotech company Ipsen to buy Kartos Therapeutics for $450 million Reuters · 22d ago
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront Endpoints News · 22d ago
- Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis Fierce Biotech · 22d ago
- Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion WSJ · 22d ago
Topics
Related trends
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity stock fell by double digits despite securing its first FDA approval for a new breast cancer treatment.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting Alzheimer’s drug sparks industry debate following mixed clinical trial results.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk has entered into a partnership with Vivani to develop a long-acting semaglutide implant designed for weight management.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.